Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin + Trametinib +/- Dabrafenib in Metastatic Melanoma
NCT02110355Phase 1Completed
- Sponsor
- Kartos Therapeutics
- Start
- Dec 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of navtemadlin in cutaneous melanoma (CM) (3 arms), sponsored by Kartos Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Safety Laboratory Tests and 2 more. Started Dec 2014; status: completed.
02
Drugs
navtemadlin
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02110355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110355.